HUTCHMED's Orpathys-Tagrisso Combination Cuts Death Risk 32% in Phase III Lung Cancer Trial

• HUTCHMED announced European and Japanese regulatory acceptance for review of Orpathys combined with Tagrisso for MET-driven, EGFR-mutated lung cancer.
• Applications target advanced non-small cell lung cancer with MET overexpression or amplification following progression on EGFR-targeted therapy.
• The filings follow a US Food and Drug Administration application submitted in September 2026.
• The Phase III SAFFRON trial showed improved survival and delayed disease progression versus platinum-based chemotherapy, with no new safety concerns.
• Results were already presented at the ESMO 2026 Presidential Symposium and simultaneously published in The New England Journal of Medicine.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611011900PRIMZONEFULLFEED9857409) on November 02, 2026, and is solely responsible for the information contained therein.